Patent · US Active

Pharmaceutical combination comprising binimetinib

US9867825B2 · kind B2 · utility

4Cited by
1References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 16, 2013
Grant dateJan 16, 2018
Priority date—
Expiry dateDec 16, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.